Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for…

A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech…

A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine…

A group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in…

Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and…

For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by…

Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat…

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell…

Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.

Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise…